All In Biotech

Drug Trial Radar · NCT04176120

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

A Multicenter Phase 3 Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Jul 1, 2020

Primary completion

Jan 25, 2024

Study completion Jun 12, 2024

Sponsor

Lead sponsor
BioTissue Holdings, IncIndustry
Sponsor type
Industry
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Conditions

  • Diabetic Foot Infection
  • Non-healing Wound
  • Non-healing Diabetic Foot Ulcer

Interventions

  • TTAX01Biological

    TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).

  • Standard CareOther

    Standard care is defined in this protocol to consist of the following: * Debridement; * Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; * Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; * A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; * Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, * Appropriate use of systemic antibiotics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete wound healingTime frame: over 26 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Clinical Research, Inc

    San Francisco, California

  • UCLA Olive View

    Sylmar, California

  • University of Miami

    Miami, Florida

  • Paley Orthopedic & Spine Institute

    West Palm Beach, Florida

  • Rosalind Franklin University

    North Chicago, Illinois

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Mount Sinai West

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • University Hospitals Richmond Medical Center

    Richmond Heights, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • JPS

    Fort Worth, Texas

  • Futuro Clinical Trials, LLC

    McAllen, Texas

  • Bio-X-Cell Research

    San Antonio, Texas

  • Foot & Ankle Institute

    St. George, Utah

  • Carilion Clinic

    Roanoke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.